December 22, 2017
Lead candidate, light-activated AU-011, currently being investigated in Phase 1b/2 study to treat ocular melanoma, an orphan indication Funding to support ongoing clinical development, enabling buildout of company infrastructure and GMP manufacturing CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle...


Experienced neuroscientist at the helm of The Brain Prize
30. June 2020
Eight promising young researchers receive Lundbeck Foundation Fellowships
16. June 2020
Denmark Gets Its First Master’s Degree Programme in Neuroscience
4. June 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge